Skip to content

Dose-Dependent Effect of Remimazolam on Preventing Emergence Delirium in Pediatric Patients Undergoing Otolaryngologic Surgery under Sevoflurane Anesthesia: A Randomized Controlled Trial?

Dose-Dependent Effect of Remimazolam on Preventing Emergence Delirium in Pediatric Patients Undergoing Otolaryngologic Surgery under Sevoflurane Anesthesia: A Randomized Controlled Trial?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121148
Enrollment
Unknown
Registered
2026-03-26
Start date
2026-03-30
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophy of the tonsils with hypertrophy of the adenoids

Interventions

R1 Group (Remazolam 0.1 mg/kg Group):Intravenous push of remazolam 0.1 mg/kg at the end of surgery during skin suturing
R2 Group (Remazolam 0.2 mg/kg Group):Intravenous push of remazolam 0.2 mg/kg at the end of surgery during skin suturing
R3 Group (Remazolam 0.3 mg/kg Group):Intravenous push of remazolam 0.3 mg/kg at the end of surgery during skin suturing
P Group (Placebo Group):Intravenous push of equivalent volume of normal saline at the end of surgery during skin suturing

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Age between 3 and 6 years; 2. American Society of Anesthesiologists (ASA) physical status classification I or II; 3. Scheduled to undergo elective adenoidectomy and/or tonsillectomy under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Allergy to remimazolam or benzodiazepine drugs; 2. History of neurological or psychiatric disorders (e.g., epilepsy, autism, developmental delay); 3. Recent upper respiratory tract infection with fever within 2 weeks; 4. Severe hepatic or renal dysfunction; 5. Severe obstructive sleep apnea (apnea-hypopnea index = 5.0); 6. Abnormal cardiac function; 7. Bradycardia (heart rate < 60 beats per minute); 8. Long-term use of sedatives, analgesics, or anticonvulsants.

Design outcomes

Primary

MeasureTime frame
Incidence of emergence delirium;

Secondary

MeasureTime frame
Incidence of Severe Emergence Delirium;Extubation Time;Emergence Time;FLACC (Face, Legs, Activity, Cry, Consolability) scale was used to assess postoperative pain intensity in pediatric patients at 0, 5, 10, 20, and 30 minutes after emergence from anesthesia.;PACU stay time;Pain intensity, MAP, SpO2, and HR were measured every 10 minutes for 30 minutes after extubation.;Proportion of children requiring rescue analgesia (sufentanil) and management of emergence delirium (propofol).;Parental satisfaction was self-reported 24 hours postoperatively using the Numeric Rating Scale (NRS, range 0-10).;Incidence of Adverse Events;

Countries

China

Contacts

Public ContactPang Yong

Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College

7821602@qq.com+86 158 0817 9936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026